Cost-utility analysis of cemented hemiarthroplasty versus hydroxyapatite-coated uncemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures: the World Hip Trauma Evaluation 5 (WHiTE 5) trial. (1st August 2022)

• Record Type: Journal Article
• Authors: Png, May Ee; Petrou, Stavros; Fernandez, Miguel A.; Achten, Juul; Parsons, Nicholas; McGibbon, Alwin; Gould, Jenny; Griffin, Xavier L.; Costa, Matthew L.
• Is Part Of: Bone & joint journal. Volume 104B:Number 8(2022)
• Page Start: 922
• Page End: 928
• Publication Date: 2022-08-01
• Subjects: Cost -- Effectiveness -- Cement -- Hip -- Hemiarthroplasty -- displaced intracapsular hip fractures -- hydroxyapatite -- uncemented hemiarthroplasty -- cemented hemiarthroplasty -- cemented implants -- Trauma -- multicentre randomized controlled trial -- sensitivity analysis -- hip fractures; Bones -- Surgery -- Periodicals; Joints -- Surgery -- Periodicals; Orthopedic surgery -- Periodicals; 617.47005
• DOI: 10.1302/0301-620X.104B8.BJJ-2022-0417.R1
• Languages: English
• ISSNs: 2049-4394

Abstract

Abstract : Aims: The aim of this study was to compare the cost-effectiveness of cemented hemiarthroplasty (HA) versus hydroxyapatite-coated uncemented HA for the treatment of displaced intracapsular hip fractures in older adults. Methods: A within-trial economic evaluation was conducted based on data collected from the World Hip Trauma Evaluation 5 (WHiTE 5) multicentre randomized controlled trial in the UK. Resource use was measured over 12 months post-randomization using trial case report forms and participant-completed questionnaires. Cost-effectiveness was reported in terms of incremental cost per quality-adjusted life year (QALY) gained from the NHS and personal social service perspective. Methodological uncertainty was addressed using sensitivity analysis, while decision uncertainty was represented graphically using confidence ellipses and cost-effectiveness acceptability curves. Results: The base-case analysis showed that cemented implants were cost-saving (mean cost difference -£961 (95% confidence interval (CI) -£2, 292 to £370)) and increased QALYs (mean QALY difference 0.010 (95% CI 0.002 to 0.017)) when compared to uncemented implants. The probability of the cemented implant being cost-effective approximated between 95% and 97% at alternative cost-effectiveness thresholds held by decision-makers, and its net monetary benefit was positive. The findings remained robust against all the pre-planned sensitivity analyses. Conclusion: This study shows that cemented HA is cost-effective compared with hydroxyapatite-coated uncemented HA in older adults with displaced intracapsular hip fractures. Cite this article: Bone Joint J 2022;104-B(8):922–928.